Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.56 |
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9160047 | 0.98 | FAAH (0.59) | FAAHCASP2DNM1CNR1NAAA | |
| SCHEMBL9153941 | 0.98 | FAAH (0.59) | FAAHCASP2DNM1CNR1NAAA | |
| SCHEMBL10798719 | 0.93 | CASP2 (0.65) | FAAHCASP2DNM1NAAAEPHX2 | |
| SCHEMBL24132894 | 0.93 | CASP2 (0.65) | FAAHCASP2DNM1NAAAEPHX2 | |
| SCHEMBL22664244 | 0.93 | CASP2 (0.65) | FAAHCASP2DNM1NAAAEPHX2 | |
| SCHEMBL24910060 | 0.93 | CASP2 (0.65) | FAAHCASP2DNM1NAAAEPHX2 | |
| SCHEMBL10798712 | 0.93 | CASP2 (0.65) | FAAHCASP2DNM1NAAAEPHX2 | |
| SCHEMBL24489957 | 0.93 | CASP2 (0.65) | FAAHCASP2DNM1NAAAEPHX2 | |
| SCHEMBL13375745 | 0.93 | CASP2 (0.58) | FAAHCASP2DNM1CNR1NAAA | |
| SCHEMBL26192970 | 0.91 | CASP2 (0.61) | FAAHCASP2DNM1NAAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | MEDSHINE DISCOVERY INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | PSMA6, PSMC1, PSMA1 | FAAH 1469/4885CASP2 1158/4885DNM1 1540/4885 |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | FAAH 1049/4885CASP2 144/4885DNM1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.